Drug intelligence / Profile preview

23-valent pneumococcal polysaccharide vaccine (Ab&B Bio-tech)

Development stage: Unknown
Lead developer: Ab&B Bio-tech Co., Ltd.
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

23-valent pneumococcal polysaccharide vaccine (PPV23) is a biologic vaccine developed by Ab&B Bio-tech Co., Ltd.JS for the prevention of pneumococcal disease. The vaccine contains purified capsular polysaccharides from 23 different serotypes of Streptococcus pneumoniae, which are the primary targets for inducing protective immunity. It is designed for use in individuals aged 2 years and older to prevent conditions such as pneumonia and invasive pneumococcal disease. As of 2024, the vaccine has completed Phase I clinical trials, demonstrating a favorable safety and immunogenicity profile compared to established controls.

Other names: PPV23PPV-23PPV 2323-valent pneumococcal polysaccharide vaccinepneumococcal vaccine polyvalent

Beyond the preview

Go deeper on 23-valent pneumococcal polysaccharide vaccine (Ab&B Bio-tech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 23-valent pneumococcal polysaccharide vaccine (Ab&B Bio-tech).

Explore the full profile